1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Pathway Analyzer for the Rational Application and Combinations of Protein Kinase Inhibitor Drugs in Oncology: From Bench to Bedside

Protein kinases are key regulators of cell function that constitute one of the largest and most functionally diverse gene families with approximately 518 kinases encoded by the human genome. They direct the activity, localization and overall function of many proteins, and serve to orchestrate the activity of almost all cellular pathways. Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiological constraints on growth and survival.
To date, the industry is developing cancer drugs targeting close to 30% of all known human protein kinases and 29 kinase inhibitors have so far received approval as cancer treatments. As kinase signaling cascades involve an intricate array of interconnected circuits we need to develop more sophisticated modeling of how they are reprogrammed in response to oncogenic events and in the presence of inhibitors. This information will be vital to more rational application and combinations of different inhibitors dependent on the molecular profile of the tumor.

BioSeeker's "Pathway Analyzer for the Rational Application and Combinations of Protein Kinase Inhibitor Drugs in Oncology: From Bench to Bedside" is a novel tool for instant, interactive pathway modeling on close to 725 protein kinase inhibitor drugs across more than 125 different kinase targets or 95 different tumor types. It serves the purpose of giving you a breakdown analysis of how successful the industry is today in targeting various signaling pathways with kinase inhibitors in oncology or to research new treatment options with the same. You dynamically control the pathway modeling with up to 24 different parameter settings, including both traditional drug development data such as status, indication etc. as well as system biology information such as mutation profile, protein expression, pathway etc. Moreover, each parameter supports multi-select options and can be used as either an inclusion or exclusion parameter for your modeling. Furthermore, your modeling and analysis results are presented to you in a report supported by graphical visualization aids such as charts, diagrams and tables. As an additional value this tool also gives you instant access to extensive drug developmental profiles of all 724 protein kinase inhibitor drugs included.

All together this tool gives you superiority in access and control over drug development options when it comes to protein kinase inhibitors in oncology, not commercially available anywhere else.

The Pathway Analyzer is delivered to you electronically as a desktop application which runs locally. One year of free data and feature updates is included in your purchase.

System Requirements
- Operating system: Windows (2000/XP/Vista/7/8) for Mac Users the service is only available online
- Browser Application (Internet Explorer, Firefox, Chrome, Safari)
- Internet access (to access related internet resources)

Table Of Contents

Pathway Analyzer for the Rational Application and Combinations of Protein Kinase Inhibitor Drugs in Oncology: From Bench to Bedside

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Sunitinib Malate Market: By Disease (Pancreatic Neuroendocrine Tumors & Kidney Cancer) & By Region (Europe, North America, Asia-Pacific & Rest of the World (RoW))-Forecast (2016-2021)

Sunitinib Malate Market: By Disease (Pancreatic Neuroendocrine Tumors & Kidney Cancer) & By Region (Europe, North America, Asia-Pacific & Rest of the World (RoW))-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Sunitinib, developed and marketed as Sutent by Pfizer Inc and previously known as SU11248, is a small-molecule medicine which has to be administered orally and has been proven to be effective in blocking ...

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

  • $ 4995
  • Industry report
  • September 2016
  • by GBI Research

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies Summary Gastric cancer is characterized by the formation of malignant ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.